Fennec Pharmaceuticals (FENC) Stock Statistics & Valuation Metrics

Fennec Pharmaceuticals has a market cap or net worth of $344.94M. The enterprise value is $243.62M.

Fennec Pharmaceuticals has 34,737,030 shares outstanding. The number of shares has decreased by -2.65% in one year.

Fennec Pharmaceuticals’s return on equity (ROE) is -0.29 and return on invested capital (ROIC) is -11.52%.

The current PE Ratio of Fennec Pharmaceuticals is 256.4. Fennec Pharmaceuticals’s PEG ratio is -0.01.

In the last 12 months, Fennec Pharmaceuticals had revenue of 45.42M and earned -10.27M in profits. Earnings per share was -0.36.

In the last 12 months, operating cash flow was -7.86M and capital expenditures -4.00, giving a free cash flow of -7.86M billion.

Fennec Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―

Fennec Pharmaceuticals upcoming earnings date is Aug 6, 2026, TBA (Confirmed).

Fennec Pharmaceuticals as a current ratio of 6.34, with Debt / Equity ratio of 0.00%

In the past 12 months, Fennec Pharmaceuticals has paid 0.00 in taxes.

Fennec Pharmaceuticals EV to EBITDA ratio is -26.79, with an EV/FCF ratio of -12.53.

Fennec Pharmaceuticals has $40.08M in cash and marketable securities with $0.00 in debt, giving a net cash position of $40.08M billion.

Gross margin is 92.23%, with operating margin of -15.11%, and net profit margin of -22.62%.

The average price target for Fennec Pharmaceuticals is $15.50, which is 11.43% higher than the current price. The consensus rating is Strong Buy